TR201109686T2 - Olmesartan'ın Farmasötik Bileşimleri. - Google Patents

Olmesartan'ın Farmasötik Bileşimleri.

Info

Publication number
TR201109686T2
TR201109686T2 TR2011/09686T TR201109686T TR201109686T2 TR 201109686 T2 TR201109686 T2 TR 201109686T2 TR 2011/09686 T TR2011/09686 T TR 2011/09686T TR 201109686 T TR201109686 T TR 201109686T TR 201109686 T2 TR201109686 T2 TR 201109686T2
Authority
TR
Turkey
Prior art keywords
olmesartan
pharmaceutical compositions
found
summary content
pharmaceutical
Prior art date
Application number
TR2011/09686T
Other languages
English (en)
Inventor
Far�� Ferhat
Avci Recep
S�Ylemez Serdar
Ko� F�Kret
Ekmek��Yan Nad�N
Original Assignee
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ filed Critical Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Publication of TR201109686T2 publication Critical patent/TR201109686T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Özet içeriği bulunamadı.
TR2011/09686T 2008-12-30 2008-12-30 Olmesartan'ın Farmasötik Bileşimleri. TR201109686T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/055572 WO2010076596A1 (en) 2008-12-30 2008-12-30 Pharmaceutical formulations of olmesartan

Publications (1)

Publication Number Publication Date
TR201109686T2 true TR201109686T2 (tr) 2012-03-21

Family

ID=40852166

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/09686T TR201109686T2 (tr) 2008-12-30 2008-12-30 Olmesartan'ın Farmasötik Bileşimleri.

Country Status (9)

Country Link
US (1) US20110256221A1 (tr)
EP (1) EP2387392B1 (tr)
JP (1) JP2012513978A (tr)
BR (1) BRPI0823402A2 (tr)
CA (1) CA2748409C (tr)
EA (1) EA201170913A1 (tr)
ES (1) ES2404811T3 (tr)
TR (1) TR201109686T2 (tr)
WO (1) WO2010076596A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081376B2 (ja) * 2011-12-28 2017-02-15 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
CN102716100B (zh) * 2012-07-12 2013-08-07 南京正大天晴制药有限公司 一种含奥美沙坦酯的片剂及其制备方法
WO2014188729A1 (ja) * 2013-05-24 2014-11-27 持田製薬株式会社 経口用組成物
JP6653116B2 (ja) * 2014-08-27 2020-02-26 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
JP6765473B2 (ja) * 2019-05-09 2020-10-07 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
CN111557924B (zh) * 2020-05-13 2022-05-10 重庆赛凌医药有限公司 一种奥美沙坦酯氢氯噻嗪片的制备方法及奥美沙坦酯氢氯噻嗪片

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
CA2494707A1 (en) * 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
US20060074117A1 (en) * 2004-09-02 2006-04-06 Lilach Hedvati Purification of olmesartan medoxomil
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
US20060281800A1 (en) * 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
GB0710905D0 (en) * 2007-06-07 2007-07-18 Generics Uk Ltd Amorphous olmesartan medoxomil
ES2510866T3 (es) * 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo

Also Published As

Publication number Publication date
WO2010076596A1 (en) 2010-07-08
JP2012513978A (ja) 2012-06-21
CA2748409A1 (en) 2010-07-08
US20110256221A1 (en) 2011-10-20
EP2387392A1 (en) 2011-11-23
EP2387392B1 (en) 2013-02-20
BRPI0823402A2 (pt) 2015-06-16
EA201170913A1 (ru) 2012-01-30
ES2404811T3 (es) 2013-05-29
CA2748409C (en) 2016-03-08

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY153915A (en) Organic compounds
EA201170832A1 (ru) Пуриновые соединения
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201170227A1 (ru) Имидазолкарбоксамиды
EA200802008A1 (ru) Фармацевтические композиции
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
ATE469895T1 (de) Cgrp-rezeptorantagonisten
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
PA8792401A1 (es) Fenilendiaminas
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
SG158091A1 (en) Imidazoazepinone compounds